Study to Evaluate the Efficacy and Safety of P-3074 Topical Solution in the Treatment of Androgenetic Alopecia

Alopecia, Androgenetic Clinical Trial

Official title:

A Multicentre, Randomized, Double-blind, Parallel-group, Controlled Study, to Assess the Efficacy and Safety of P-3074 Cutaneous Spray, Solution, in the Treatment of Male Pattern Baldness

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03004469
• Other study ID #: PM1541
• Status: Completed
• Phase: Phase 3
• Start date: August 2, 2016
• Est. completion date: March 5, 2018

Study information

• Verified date: June 2019
• Source: Polichem S.A.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to confirm the clinical efficacy and the safety of P-3074 in participants with androgenetic alopecia.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 458
• Est. completion date: March 5, 2018
• Est. primary completion date: March 5, 2018
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years to 40 Years

Eligibility

Inclusion Criteria:

• Written informed consent before starting any study related procedures;

• Men 18 to 40 years of age;

• Men with mild to moderate vertex male pattern hair loss according to a modified Norwood/Hamilton classification scale (III vertex, IV or V);

• Participants willing to have a tattoo in the target area;

• Outpatients;

• Ability to comprehend the full nature and purpose of the study, including possible risks and side effects;

• Ability to co-operate with the Investigator and to comply with the requirements of the entire study.

Exclusion Criteria:

• Clinically relevant abnormal skin scalp findings which could interfere with the aim of the study; in particular, abrasion, actinic keratosis, inflammatory disorders or any other abnormality;

• Participants who had had hair transplant surgery or hair weaving;

• Clinically relevant abnormal laboratory values indicative of physical illness;

• Ascertained or presumptive hypersensitivity to the active principle and/or formulations' ingredients; history of anaphylaxis to drugs or allergic reactions in general, which the Investigator considers may affect the outcome of the study;

• History of local infections of skin and subcutaneous tissues of the head in the 3-months period before the trial inclusion;

• Relevant history of renal, hepatic, gastrointestinal, cardiovascular, respiratory, skin, haematological, endocrine or neurological diseases, that may interfere with the aim of the study;

• Suspicion of malignancy, including prostate cancer;

• History of infertility or difficulty fathering children;

• Participants who wish to conceive children during the study or whose sexual partner(s) is pregnant;

• Participants with active seborrheic dermatitis;

• History of varicocele;

• Concurrent use of systemic corticosteroids, topical corticosteroids in the balding area studied, anabolic steroids, or over-the-counter "hair restorers";

• Use of the following drugs with antiandrogenic properties within 6 months of study entry: flutamide, cyproterone acetate, estrogen, progesterone, cimetidine, spironolactone or ketoconazole;

• Participants who had been treated with any of the following drugs within the past year: minoxidil (topical or oral), zidovudine, cyclosporine, diazoxide, phenytoin, systemic interferon, psoralens, streptomycin, penicillamine, benoxaprofen, tamoxifen, phenothiazines or cytotoxic agents;

• Use of finasteride or dutasteride within previous 12 months;

• Light or laser treatment of scalp within previous 3 months;

• Participation in the evaluation of any drug for 3 months before this study, calculated from the first day of the month following the last visit of the previous study;

• History of drug, alcohol [>2 drinks/day defined according to USDA Dietary Guidelines 2010], caffeine (>5 cups coffee/tea/day) or tobacco abuse (10 cigarettes/day).

Related Conditions & MeSH terms

• Alopecia
• Alopecia Areata
• Alopecia, Androgenetic

Intervention

Drug:
• P-3074

• Finasteride

• P-3074 Vehicle

• Finasteride Placebo

Locations

Country	Name	City	State
Belgium	Site #102	Brussel
Belgium	Site #103	Brussels
Belgium	Site #104	Brussels
Belgium	Site #101	Gent
Germany	Site #211	Augsburg
Germany	Site #202	Berlin
Germany	Site #212	Berlin
Germany	Site #216	Bochum
Germany	Site #210	Dresden
Germany	Site #217	Dresden
Germany	Site #221	Dresden
Germany	Site #203	Dusseldorf
Germany	Site #204	Freiburg
Germany	Site #206	Hamburg
Germany	Site #214	Hamburg
Germany	Site #218	Hamburg
Germany	Site #213	Hannover
Germany	Site #215	Karlsruhe
Germany	Site #220	Lübeck
Germany	Site #208	Münster
Germany	Site #219	Potsdam
Germany	Site #209	Schwerin
Germany	Site #201	Wuppertal
Hungary	Site #303	Budapest
Hungary	Site #309	Budapest
Hungary	Site #302	Debrecen
Hungary	Site #308	Satoraljaujhely
Hungary	Site #301	Szolnok
Hungary	Site #307	Szombathely
Russian Federation	Site #401	Chelyabinsk
Russian Federation	Site #402	Moscow
Russian Federation	Site #407	Moscow
Russian Federation	Site #411	Moscow
Russian Federation	Site #409	Rostov
Russian Federation	Site #403	Ryazan
Russian Federation	Site #406	Saint-Petersburg
Russian Federation	Site #408	Saint-Petersburg
Russian Federation	Site #410	Yaroslavl
Spain	Site #503	Alicante
Spain	Site #505	Barakaldo
Spain	Site #502	Barcelona
Spain	Site #507	Cordoba
Spain	Site #501	Madrid
Spain	Site #504	Madrid
Spain	Site #508	Madrid
Spain	Site #506	Pamplona

Sponsors (1)

Lead Sponsor	Collaborator
Polichem S.A.

Countries where clinical trial is conducted

Belgium,  Germany,  Hungary,  Russian Federation,  Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Adjusted Mean Change From Baseline in Hair Growth Assessed by Target Area Hair Count (TAHC) in the Vertex at Week 24	The change from baseline in the TAHC within a 1 cm^2 (square centimeter) of baldness area at Week 24, were assessed by macro photographic techniques analysis. The Investigator selected a target area in the anterior leading edge of the vertex thinning area. A small dot tattoo was placed in the center of the circle of the clipped hairs. Using the tattoo as a reference point, the circular area was photographed and a 1 cm^2 circular area within the target area was analysed. Change is the adjusted mean of Week 24 minus baseline.The analysis uses a covariance pattern model adjusted for treatment group, center, visit and treatment-by-visit interaction as fixed effects and baseline hair count as a covariate with an unstructured covariance structure.	Baseline and Week 24
Secondary	Adjusted Mean Change From Baseline in Hair Growth Assessed by TAHC in the Vertex at Week 12	The change from baseline in the TAHC within a 1 cm^2 of baldness area at Week 12, were assessed by macro photographic techniques analysis. The Investigator selected a target area in the anterior leading edge of the vertex thinning area. A small dot tattoo was placed in the center of the circle of the clipped hairs. Using the tattoo as a reference point, the circular area was photographed and a 1 cm^2 circular area within the target area was analysed. Change is the adjusted mean of Week 24 minus baseline.The analysis uses a covariance pattern model adjusted for treatment group, center, visit and treatment-by-visit interaction as fixed effects and baseline hair count as a covariate with an unstructured covariance structure.	Baseline and Week 12
Secondary	Adjusted Mean Change From Baseline in Target Area Hair Width (TAHW) in the Vertex at Weeks 12 and 24	The change from baseline in the TAHW within a 1 cm^2 of baldness area at Weeks 12 and 24, were assessed by macro photographic techniques analysis. The Investigator selected a target area in the anterior leading edge of the vertex thinning area. A small dot tattoo was placed in the center of the circle of the clipped hairs. Using the tattoo as a reference point, the circular area was photographed and a 1 cm^2 circular area within the target area was analysed. Change is the adjusted mean of Weeks 12 and 24 minus baseline, respectively.The analysis uses a covariance pattern model adjusted for treatment group, center, visit and treatment-by-visit interaction as fixed effects and baseline hair count as a covariate with an unstructured covariance structure.	Baseline, Week 12 and Week 24
Secondary	Adjusted Mean Overall Male Hair Growth Questionnaire (MHGQ) Score as Assessed by the Participant at Weeks 12 and 24	Participants assessed their scalp hair using a validated, self-administered MHGQ, which was given in their language. The self-administered MHGQ overall score assessed using the following 5-point scale: 1 = very satisfied, 2 = satisfied, 3 = neutral (neither satisfied nor dissatisfied), 4 = dissatisfied, 5 = very dissatisfied. A higher score indicated a worse outcome. The questionnaire was administered to eligible participants to subjectively measure their perception of hair growth. A higher score indicated a worse outcome.	Week 12 and Week 24
Secondary	Adjusted Mean Change From Baseline in Participants Hair Growth/Loss Assessed for the Vertex by Investigator at Weeks 12 and 24	The local Investigator assessed change in hair growth from Baseline to Week 12 and from Baseline to Week 24, using a 7-point scale. The evaluation was done by the Investigator or designee, by comparing the global vertex view photograph obtained at baseline visit with the participants actual scalp at 12 and 24 weeks. For the purpose of assessment of changes in hair growth by Investigators screening visits (where global photos were taken) were used as Baseline. The change from Baseline in hair growth was assessed using the following 7-point scale: -3 = greatly decreased, -2 = moderately decreased, -1 = slightly decreased, 0 = no change, +1 = slightly increased, +2 = moderately increased, +3 = greatly increased. The analysis uses a covariance pattern model adjusted for treatment group, center, visit and treatment-by-visit interaction as fixed effects with an unstructured covariance structure.	Baseline, Week 12 and Week 24
Secondary	Adjusted Mean Change From Baseline in Participants Hair Growth/Loss at Weeks 12 and 24, Assessed for the Vertex by Blind Assessor	An independent blinded assessor was responsible for evaluating, under blinded conditions, the screening global photographs of the target area for all participants. They evaluated the eligibility of each participants according to the clinical inclusion criteria. The independent blinded assessor assessed the change of the hair growth from Baseline to Week 12 and from Baseline to Week 24, using a 7-point scale: -3 = greatly decreased, -2 = moderately decreased, -1 = slightly decreased, 0 = no change, +1 = slightly increased, +2 = moderately increased, +3 = greatly increased. This assessment was performed by comparing the global photographs obtained at screening visit with those subsequently obtained at Weeks 12 and 24. The analysis uses a covariance pattern model adjusted for treatment group, center, visit and treatment-by-visit interaction as fixed effects with an unstructured covariance structure.	Baseline, Week 12 and Week 24
Secondary	Adjusted Mean International Index of Erectile Function (IIEF-2) Scores at Weeks 4, 8, 12 and 24	The 15-question IIEF-2 Questionnaire (Sexual Function Questionnaire) was used to evaluate any changes in sexual function and activity, at Weeks 4, 8, 12 and 24. A score of 0-5 is awarded to each of the 15 questions that examine the 4 main domains of male sexual function: erectile function, orgasmic function, sexual desire and intercourse satisfaction. Erectile function domain has 6 questions with the score for domain range from 0-30. Orgasmic function domain has 2 questions with the score for domain range from 0-10. , Sexual desire function domain has 2 questions with the score for domain range from 0-10. Intercourse satisfaction function domain has 3 questions with the score for domain range from 0-15. Overall Satisfaction domain has 2 questions with the score for domain range from 0-10. A higher score indicated a worse outcome in that domain.	Weeks 4, 8, 12 and 24
Secondary	Local Tolerability as Assessed by Incidence Rate of Skin Irritation Event Via Severity Score for Skin Irritation Scale	Local tolerability at the application site was assessed to rate the severity of any skin irritation. The Investigator used the Severity score for skin Irritation scale to assess local tolerability. The dermal response and other effects indicative irritation responses were recorded at time of examination. Anything other than "No evidence of irritation" under Dermal Response was considered as a Dermal Response Skin Irritation event. Anything other than "No other effects" under Other Effects was considered as an Other Effects of Skin Irritation event. The event incidence rate is calculated as the number of events interest divided by total personal time in years.	Baseline to Week 24
Secondary	Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs	An Adverse event is defined as any untoward medical occurrence in a participants or clinical investigation patient administered a pharmaceutical product and which does not necessarily have to have a causal relationship with treatment. A serious AE was an AE that results in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect and medically significant event. The Treatment Emergent Adverse Events (TEAEs) is defined as all AEs occurring on or after the first dose of the IMP.	From the start of IMP up to 28 weeks